Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results
| Autor: | Francois Wilhelm, Vandana G. Abramson, Aditya Bardia, Kevin Kalinsky, Linda T. Vahdat, RL Moroose, Steven J. Isakoff, Ingrid A. Mayer, Jennifer R. Diamond, Dejan Juric, Jordan Berlin, Alexander Starodub, Nikita C. Shah, Wells A. Messersmith, Allyson J. Ocean, David M. Goldenberg, Joyce O'Shaughnessy, Robert M. Sharkey, Michael J. Guarino, Geoffrey I. Shapiro |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Gynecology Cancer Research medicine.medical_specialty Antibody-drug conjugate business.industry SN-38 medicine.disease 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Breast cancer Refractory chemistry 030220 oncology & carcinogenesis Internal medicine Relapsed refractory Sacituzumab govitecan medicine business Triple-negative breast cancer |
| Zdroj: | Journal of Clinical Oncology. 34:LBA509-LBA509 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.18_suppl.lba509 |
| Popis: | LBA509 Notice of Retraction: “Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.” ASCO's Confidentiality Policy requires that abstracts be considered confidential and embargoed from the time of submission until the findings have been publicly released in conjunction with the ASCO Annual Meeting. Abstract LBA509, published in the 2016 ASCO Annual Meeting Proceedings Part II, violated this policy and was retracted from publication and presentation at the 2016 ASCO Annual Meeting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|